npj Breast Cancer

Papers
(The H4-Index of npj Breast Cancer is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers557
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer270
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer178
Biological correlates associated with high-risk breast cancer patients identified using a computational method125
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients102
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer100
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer98
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab97
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–202194
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells87
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination81
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab79
Immunotherapy for early triple negative breast cancer: research agenda for the next decade74
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer66
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment65
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer60
International survey on invasive lobular breast cancer identifies priority research questions59
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors59
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial58
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC56
Breastfeeding attributable fraction of triple negative breast cancer in the US54
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)54
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer53
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice53
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer47
Temporal evolution of breast cancer brain metastases treatments and outcomes43
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events43
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays43
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models42
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases41
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions39
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study37
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer36
Survival outcomes after omission of surgery for ductal carcinoma in situ36
0.16903805732727